Minerva Neurosciences Appoints Dr. Gail M. Farfel to Strengthen Leadership Ahead of Phase 3 Trial
- Neurvati Neurosciences appointed Dr. Gail M. Farfel to its board to enhance leadership for upcoming Phase 3 trial of radiprodil.
- Dr. Farfel brings over 30 years of neuroscience experience, crucial for developing treatments for neurological disorders.
- Neurvati is poised for growth with recent financing and partnerships, aiming to advance therapies for GRIN-NDD and other disorders.
Neurvati Neurosciences Strengthens Leadership with Appointment of Dr. Gail M. Farfel
Neurvati Neurosciences, a clinical-stage biotechnology firm dedicated to developing therapies for neurological and psychiatric disorders, makes a significant strategic move with the recent appointment of Dr. Gail M. Farfel to its board of directors. This development occurs as Neurvati prepares to launch a critical Phase 3 trial for radiprodil, a treatment targeting GRIN-related neurodevelopmental disorder (GRIN-NDD). Dr. Farfel brings over 30 years of invaluable experience in neuroscience research, which is anticipated to bolster the company's mission to expedite the development of groundbreaking treatments in the field.
Dr. Farfel's extensive background includes leadership positions at industry giants such as Zogenix, Novartis, and Pfizer, as well as a tenure as CEO of ProMIS Neurosciences. Her expertise is reflected in more than 50 scientific publications in neuropsychopharmacology, underlining her substantial contributions to the understanding and treatment of neurological disorders. Deborah Dunsire, MD, Chairwoman of the boards for both Neurvati and GRIN Therapeutics, emphasizes that Dr. Farfel's insights will be critical during this pivotal period, particularly as the companies aim to bring innovative therapies to patients in need. The collaboration with Angelini Pharma further enhances Neurvati's global presence, facilitating broader access to its promising treatments.
The appointment comes at a time when Neurvati and GRIN are experiencing noteworthy growth, marked by a recent Series D financing and a licensing agreement. These developments signal the companies' commitment to advancing their therapeutic pipelines and expanding their reach in the treatment of GRIN-NDD and other serious neurodevelopmental disorders. Dr. Farfel's academic credentials, including a Bachelor's in biochemistry from the University of Virginia and a PhD in neuropsychopharmacology from the University of Chicago, establish her as a leading figure in the neuroscience community, making her a valuable asset to Neurvati's board as it navigates this crucial phase in its evolution.
In conclusion, Dr. Gail M. Farfel's appointment to Neurvati Neurosciences' board of directors represents a strategic enhancement to the company's leadership as it prepares for significant clinical milestones. Her wealth of experience and expertise in neuroscience is expected to provide critical guidance as Neurvati aims to develop first-in-class treatments for patients with challenging neurodevelopmental disorders. With the backing of a solid financial foundation and strategic partnerships, Neurvati is poised for an impactful future in the biotechnology landscape.